Autopsy report · NCT03045393

Mirvetuximab Soravtansine (IMG853) in Folate Receptor Alpha-expressing TNBC

“Inadequate enrollment”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1

Sponsor

Duke University

Sponsor type

University, hospital or other

Conditions

Breast Cancer Triple Negative

Interventions

Mirvetuximab Soravtansine (IMGN853)

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Prophylactic Phenobarbital After Neonatal Seizures
  “Inadequate rate of enrollment” (92% match in meaning)
• Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma
  “Lack of enrollment” (92% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.